Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) by 24.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 183,601 shares of the company’s stock after buying an additional 35,635 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.14% of Cytek Biosciences worth $1,017,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. SlateStone Wealth LLC bought a new stake in shares of Cytek Biosciences during the 2nd quarter valued at about $70,000. Olympiad Research LP bought a new position in shares of Cytek Biosciences during the third quarter valued at approximately $72,000. Everence Capital Management Inc. grew its holdings in shares of Cytek Biosciences by 20.9% during the third quarter. Everence Capital Management Inc. now owns 16,760 shares of the company’s stock valued at $93,000 after purchasing an additional 2,900 shares during the last quarter. Dark Forest Capital Management LP raised its position in shares of Cytek Biosciences by 85.3% during the 2nd quarter. Dark Forest Capital Management LP now owns 21,098 shares of the company’s stock worth $118,000 after purchasing an additional 9,711 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Cytek Biosciences in the 3rd quarter worth approximately $128,000. Institutional investors own 69.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler upped their price objective on Cytek Biosciences from $8.00 to $8.50 and gave the stock an “overweight” rating in a research note on Monday, November 11th.

Cytek Biosciences Stock Down 3.0 %

Shares of NASDAQ:CTKB opened at $6.24 on Thursday. The company’s 50-day moving average price is $6.01 and its 200 day moving average price is $5.77. The company has a market cap of $803.78 million, a PE ratio of -77.99 and a beta of 1.46. Cytek Biosciences, Inc. has a fifty-two week low of $4.66 and a fifty-two week high of $9.87.

Cytek Biosciences (NASDAQ:CTKB) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. The company had revenue of $51.50 million for the quarter, compared to analysts’ expectations of $50.63 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. As a group, equities analysts anticipate that Cytek Biosciences, Inc. will post -0.06 EPS for the current year.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.